Adial Pharmaceuticals, Inc. Unrealized Gain (Loss) on Derivatives
Adial Pharmaceuticals, Inc. (ADIL) reported Unrealized Gain (Loss) on Derivatives of -$193.88 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2024-04-01
- Adial Pharmaceuticals, Inc. unrealized gain (loss) on derivatives for the quarter ending 2023-12-31 was -$195.57K, a 160.18% decline year-over-year.
- Adial Pharmaceuticals, Inc. unrealized gain (loss) on derivatives for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Adial Pharmaceuticals, Inc. unrealized gain (loss) on derivatives for the quarter ending 2023-06-30 was $15.69K.
- Adial Pharmaceuticals, Inc. unrealized gain (loss) on derivatives for the quarter ending 2023-03-31 was -$14.00K, a 109.59% decline year-over-year.
- Adial Pharmaceuticals, Inc. unrealized gain (loss) on derivatives for fiscal 2023 was -$193.88K, a 137.14% decline from fiscal 2022.
- Adial Pharmaceuticals, Inc. unrealized gain (loss) on derivatives for fiscal 2022 was $522.00K.
- Adial Pharmaceuticals, Inc. unrealized gain (loss) on derivatives for fiscal 2021 was -$281.71K.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$195.57K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$195.57K derived: sum of 2 quarters · filed 2024-04-01 | -$179.88K derived: sum of 3 quarters · filed 2024-04-01 | -$193.88K 10-K · filed 2024-04-01 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-14 | $15.69K derived: sum of 2 quarters · filed 2023-11-14 | $1.69K 10-Q · filed 2023-11-14 | $326.69K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | $15.69K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-10-30 | $1.69K 10-Q/A · filed 2023-10-30 | $326.69K derived: sum of 3 quarters · filed 2023-10-30 | $401.69K derived: sum of 4 quarters · filed 2023-10-30 |
| 2023-03-31 | -$14.00K 10-Q · filed 2023-05-12 | $311.00K derived: sum of 2 quarters · filed 2023-05-12 | $386.00K derived: sum of 3 quarters · filed 2023-05-12 | $362.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | $325.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $400.00K derived: sum of 2 quarters · filed 2023-03-30 | $376.00K derived: sum of 3 quarters · filed 2023-03-30 | $522.00K 10-K · filed 2023-03-30 |
| 2022-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $51.00K derived: sum of 2 quarters · filed 2022-11-14 | $197.00K 10-Q · filed 2022-11-14 | $251.01K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-06-30 | -$24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $122.00K 10-Q · filed 2022-08-15 | $176.01K derived: sum of 3 quarters · filed 2023-05-12 | -$98.51K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-03-31 | $146.00K 10-Q · filed 2023-05-12 | $200.01K derived: sum of 2 quarters · filed 2023-05-12 | -$74.51K derived: sum of 3 quarters · filed 2023-05-12 | -$141.99K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $54.01K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$220.51K derived: sum of 2 quarters · filed 2023-03-30 | -$287.99K derived: sum of 3 quarters · filed 2023-03-30 | -$281.71K 10-K · filed 2023-03-30 |
| 2021-09-30 | -$274.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$342.00K derived: sum of 2 quarters · filed 2022-11-14 | -$335.73K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$67.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$61.20K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $6.28K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |